Case Report

# Cornelia de Lange Syndrome Caused by an Intragenic Heterozygous Deletion in RAD21 Detected through Very-High-Resolution Chromosomal Microarray Analysis 

Hugo H. Abarca-Barriga 1,2,* © , Renzo Punil Luciano ${ }^{2}$ and Flor Vásquez Sotomayor ${ }^{1,2}$<br>1 Instituto de Investigaciones de Ciencias Biomédicas, Universidad Ricardo Palma, Lima 15039, Peru; fvasquezso@insn.gob.pe<br>2 Servicio de Genética \& Errores Innatos del Metabolismo, Instituto Nacional de Salud del Niño Breña, Lima 15083, Peru; rpunil@insn.gob.pe<br>* Correspondence: hugo.abarca@urp.edu.pe; Tel.: +51-979301132

Citation: Abarca-Barriga, H.H.; Punil Luciano, R.; Vásquez Sotomayor, F. Cornelia de Lange Syndrome Caused by an Intragenic Heterozygous Deletion in RAD21 Detected through Very-High-Resolution Chromosomal Microarray Analysis. Genes 2023, 14, 2212. https://doi.org/10.3390/ genes14122212

Academic Editors: Chuntao Zhao and Jingyun Yang

Received: 3 October 2023
Revised: 31 October 2023
Accepted: 2 November 2023
Published: 14 December 2023


Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).


#### Abstract

Cornelia de Lange syndrome is a genetic and clinically heterogeneous entity, caused by at least five genes. It is characterized by short stature, gestalt facies, microcephaly, neurodevelopmental disorders, and other anomalies. In this report, we present a 13-year-old female patient with microcephaly, cleft palate, polydactyly, short stature, triangular facies, frontal bossing, a bulbous nose, an overfolded helix, limited pronosupination, and an anomalous uterus. No neurodevelopmental disorders were reported. A chromosomal microarray analysis of 6.5 million markers was performed in the proband and her parents. The results showed a de novo heterozygous microdeletion of exons 9-14 within RAD21, which confirmed the diagnosis of Cornelia de Lange syndrome type 4 . Our patient did not show any neurologic phenotype (until the time of diagnosis), although neurodevelopmental disorders are frequently present in patients with Cornelia de Lange syndrome type 4, and despite carrying a deletion that was larger than previously reported. Therefore, unknown genetic modifiers or intrinsic mechanisms of RAD21 variants may exist and should be studied.


Keywords: RAD21; de Lange syndrome; microarray analysis; gene deletion

## 1. Introduction

Cornelia de Lange syndrome (CdLS, OMIM PS122470) comprises a group of conditions that are diverse in their genetic origin and clinical manifestations [1,2]. The prevalence has been reported to be 1/10,000-100,000, although it is thought to be higher [3-5]. Five genes (NIPBL, SMC1A, HDAC8, RAD21, and SMC3) have been associated with CdLS phenotypes of autosomal dominant or X-linked inheritance [3].

Among other clinical manifestations, patients usually show short stature, thick eyebrows, synophrys, a depressed nasal bridge, a short nose, anteverted nares, a long and smooth philtrum, and a thin and tented upper lip vermilion [2]. The prenatal proportional short stature is characterized by anthropometry at birth below percentile 10 , followed by postnatal growth below percentile 5 [4].

There is a consensus on the diagnostic criteria of CdLS with a score greater than 11 on the International Consensus Statement [2], including microcephaly, oligodactyly or adactyly, congenital diaphragmatic hernia, development delay, intellectual disability, small hands, short feet, and hirsutism [2].

CdLS type 4 (OMIM \# 614701) patients are extremely rare, and their phenotype is associated with heterozygous variants in RAD21, although it is not fully understood how variants in this gene cause the syndrome. The most frequent clinical manifestations are motor developmental delay or intellectual disability, thick arched eyebrows, microcephaly, synophridia, short anteverted nostrils, and clinodactyly of the fifth finger [6]. Missense homozygous variants in RAD21 were associated with Mungan syndrome (OMIM \#611376).

In zebrafish, these variants appear to manifest as a loss-of-function effect of the rad21 gene. This effect showed the partial or complete absence of runx1 expression in the gut during development. The principal clinical manifestation is a chronic intestinal pseudo-obstruction without gestalt facies like CdLS $[7,8]$.

RAD21 (Gene ID: 5885, MIM *606462) is located on chromosome 8q24.11, spans 14 exons, and encodes RAD21, a 631-residue protein [9]. This protein is a structural component of the cohesion complex, which holds sister chromatids together until anaphase, ensuring the correct chromosomic segregation during mitosis [9], and is highly conserved in eukaryotes [9-11]. Additionally, RAD21 is involved in the DNA repair progression of apoptosis, centrosome cycles, gene expression, and hematopoiesis [12-17]. Regarding cohesion complex function, RAD21 is one of its components, working together with SMC1A, SMC3, and SSC3, forming a tripartite ring-like structure; therefore, variants in these genes comprise the etiology of CdL syndrome; see also [11].

In this study, we describe a female patient presenting with short stature, microcephaly, and other congenital malformations, without intellectual disability. High-resolution chromosome microarray analysis (CMA) showed a previously undescribed de novo heterozygous deletion, comprising several exons in RAD21. This copy number variation (CNV) is associated with CdLS type 4 . We review the previously reported clinical characteristics of CdLS type 4 patients and compare them with those of the patient in the current study.

## 2. Results

Clinical Evaluation
The patient, a female aged 13, is the second child of an unrelated couple of Peruvian origin (27-year-old mother and 32 -year-old father). The proband was born via cesarean section due to preeclampsia, premature rupture of membranes, and pelvic narrowing. The weight and height at birth were 3190 g (p30) and 52 cm (p86), respectively. Her motor development and school performance were adequate. At twelve days old, her clinical characteristics were a head circumference of $32 \mathrm{~cm}(-2.695$ SD), micrognathia, hypotelorism, a short neck, pre-axial polydactyly, and cleft lip and palate. At 2 years of age, the patient underwent cleft palate repair surgery. At two months, her anthropometry values included a normal height ( $59 \mathrm{~cm}, \mathrm{p} 98$ ) and microcephaly ( $\mathrm{HC}=35.5 \mathrm{~cm},-3.21 \mathrm{SD}$ ). At 3 years of age, she presented with short stature $(98.4 \mathrm{~cm},-3.346 \mathrm{SD})$, triangular facies, a broad and prominent forehead, a bulbous nose, a repaired palate (Figure 1A,B), a bilateral overfolded helix (Figure 1C,D), bilateral prono-supination limitation (Figure 2A,B), cutis marmorata (Figure 3A), hypertrichoses with a predominance in the lower limbs (Figure 3B), and overlapping toes (Figure 3C). At 12 years of age, a pelvic ultrasound showed a bicornuate uterus of 4.3 cm . The IGF-1 was low ( $167 \mathrm{ng} / \mathrm{mL}$; VR $191-482 \mathrm{ng} / \mathrm{mL}$ ), with post-stimulation growth to 60 min of $1.85 \mathrm{ng} / \mathrm{mL}$, and to 90 min of $1.81 \mathrm{ng} / \mathrm{mL}$. A full spine X-ray did not show any alterations, while a forearm X-ray showed diaphyseal curvature of the radius. At 13 years of age, a full abdomen MRI was performed, which showed a normal upper abdomen and an arcuate uterus. A TORCH test was negative.

Clinical diagnoses of some genetic diseases were not suspected, although we did not use any software (e.g., Face2Gene $2.2{ }^{\circledR}$ ); furthermore, as a first approach, a karyotype test was ordered (due to short stature), and a normal result was obtained ( $46, \mathrm{XX}$ ). Because the patient's phenotype (the absence of neurodevelopment disorders) was more likely caused by intragenic variants (single or multiple nucleotides) than a copy number variation, a high-resolution CMA test was performed. The result (arr[GRCh38] 8q24.11(116845458_116854956)x1) showed a 9499 bp heterozygous deletion in 8q24.11, comprising six exons (9-14) within RAD21. The carrier status of the parents was determined via performance of the same high-resolution CMA, which showed no deletion present in the parents. Subsequently, whole-exome sequencing was performed without pathogenic or likely-pathogenic single-variant nucleotides.


Figure 1. (A) The patient with triangular facies and large eyelashes, and without synophrys. (B) The palate repaired of the cleft without the uvula; (C) and (D) the overfolded helix and prominent helix.


Figure 2. (A) and (B) limited pronosupination in both arms.


Figure 3. (A) The patient with cutis marmorata and hypertrichosis. (B) The presence of hypertrichosis of the limbs. (C) Overlapping toes, hallux valgus, and clinodactyly of the fourth and fifth bilateral toes.

## 3. Materials and Methods

### 3.1. Ethical Statement

Following the Instituto Nacional de Salud del Niño regulations, informed written consent was obtained from the patient's parents.

### 3.2. Chromosome Microarray Analysis

Genomic DNA was isolated from whole blood using the gSYNC ${ }^{\text {TM }}$ DNA Extraction Kit (Geneaid Biotech Ltd., New Taipei City, Taiwan). Total genomic DNA (100 ng) was amplified, labeled, and hybridized using CytoScan ${ }^{\mathrm{TM}} \mathrm{XON}$ array protocols (Thermo Fischer Scientific, Waltham, MA, USA), according to the manufacturer's instructions. The array specifications included $6,550,000$ nonpolymorphic markers and approximately 300,000 SNP markers. CEL files obtained via scanning the arrays were analyzed using Chromosome Analysis Suite (ChAS) software v4.3 (Affymetrix) and Genome Build GRCh38 (hg38). Gains that affected a minimum of 50 markers, losses that affected a minimum of 25 markers, and loss of heterozygosity $(\mathrm{LOH})$ regions that expanded over 5 Mb were initially considered.

## 4. Discussion

Chromatinopathies are caused by variants in the proteins responsible for chromatin remodeling and transcriptional regulation. These variants cause a global deregulation of gene expression and, consequently, favor the appearance of intellectual disability, delayed psychomotor development, and behavioral disorders [3]. CdLS is a chromatinopathy and shares the characteristics previously described with Rubinstein-Taybi, Coffin-Siris, Wiedemann-Steiner, and KBG syndromes [3].

CdLS is caused by genetic variants in the ring-like cohesin protein complex genes. The complex comprises two regulators (NIPBL and HDAC8) and four structural proteins (SMC1A, SMC3, SCC3 and RAD21). Variants in NIPBL have been found in approximately $70 \%$ of patients. Variants in other subunits or regulators of the complex are also responsible for CdLS [3]. The cohesin complex maintains chromatin structure during cell division and transcription regulation [18]. RAD21 binds to the SMC1-SMC3 heterodimer by its conserved carboxyl-terminal and amino-terminal protein domain, respectively. RAD21 also binds SCC3 (SA1/SA2) by its STAG domain [19].

Most variants found in RAD21 are single-nucleotide variants (SNVs). However, several patients diagnosed with CdLS have been shown to carry CNVs, which span several genes, including RAD21 [8]. Here, we show a previously undescribed variant, an intragenic de novo microdeletion which comprises exons 9-14 within $R A D 21$, in a patient with no pre-established genetic diagnosis. The deletion of these exons generates a truncated protein that lacks the STAG domain and the C-terminal region, both necessary for the interaction with SMC1 and the stabilization of the cohesin complex [8]. This gene is haploinsufficient $\left(\right.$ ClinGen ${ }^{\circledR}$ shows LOEUF $=0.26$, pLI score $=1$, index haploinsufficiency $=4.51$, and HI score $=3$ ), and this deletion has a dominance effect.

To date, including the patient described in the present study, 27 patients with RAD21 variants have been reported. In many of these studies, only the genetic variants have been described, without the clinical characteristics (Table 1) [6,8,20-29]. It can also be observed that the distribution of CdLS has been similar among males and females, with the time of diagnosis having a median of 5.5 years.

The most-described clinical manifestations were microcephaly, broad eyebrows, synophrydia, long eyelashes, a long philtrum, clinodactyly, and psychomotor developmental delay (Table 1). From the 27 CdLS cases, 7 were caused by CNVs (deletions including RAD21), 7 were frameshift variants, 7 were nonsense variants, and the rest were missense and splicing variants [6,8,20-29]. In one of the reported cases, even though different technologies were used, such as Face2Gene and the CdLS diagnosis score [28], the variant described is predicted as "probably benign" according to Varsome and as "uncertain" according to Franklin [31,32]. Post hoc analysis of the phenotype of our patient did not show clinical criteria of CdLS.

It is important to highlight that the current commonly used genetic platforms are incapable of detecting all genetic variants. Moreover, a lack of information and evidence hinders the classification of most of the variants found in these studies. Until the technology and analyses are improved, we consider that CMA (normal- and high-resolution) and nextgeneration sequencing (NGS) should be used complementarily to synergistically improve their power of variant detection. Going forward, third-generation sequencing could replace conventional methods because it can detect almost all types of variants including SNVs and CNVs, while NGS primarily detects SNVs and CNVs, failing to achieve the same level of sensitivity as CMA [30].

Table 1. Clinical characteristics of patients with Cornelia de Lange syndrome type 4.

|  | Deardorff et al. $2012[19](\mathrm{n}=6)$ |  |  |  |  |  | $\begin{aligned} & \text { Minor et al. } \\ & 2014 \text { [21] } \\ & (\mathrm{n}=2) \end{aligned}$ |  | Ansariet al. 2014$[20](n=1)$ | Lee et al. 2014 [22] ( $\mathrm{n}=1$ ) | Martinezet al. 2017 [23] ( $\mathrm{n}=1$ | Boyle et al. $2017[24](\mathrm{n}=4)$ |  |  |  | Yuan et al. 2019 [25] ( $\mathrm{n}=2$ ) |  | $\begin{gathered} \text { Kruszza et al. } 2019 \\ {[26](\mathrm{n}=3)} \end{gathered}$ |  |  | Gudmunson <br> et al. 2019 <br> [6] $(\mathrm{n}=1)$ | Dorval et al. $2019[27]$ <br> ( $\mathrm{n}=1$ ) | Latorre-Pellicer et al. 2020 [28] |  |  | $\begin{aligned} & \text { Leie et al. } \\ & \begin{array}{c} 2020 \\ (299] \\ (\mathrm{n}=1) \end{array} \end{aligned}$ | Abarca et al. <br> 2023 [30] <br> ( $\mathrm{n}=1$ ) | Total ( $\mathrm{N}=26$ ) | (\%) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 1 | 2 | 3 | 4 | 5 | 6 | 1 | 2 |  |  |  | 1 | 2 | 3 | 4 | 1 | 2 | 1 | 2 | 3 |  |  | 1 | ${ }_{2}$ | 3 |  |  |  |  |
| Sex | * | M | * | * | * | + | M | M | F | * | * | F | F | F | F | * | * | F | M | m | M | м | F | F | M | M | F | $\mathrm{F}=9 / \mathrm{M}=9 / *=9$ |  |
| Age (years) | * | * | * | * | * | * | 3 | 12 |  | 4 | * | 26 | * | * | * | * | * | 7 | 14 | 2 | 1.25 | 5 | 3 | 5 | 8 | 6 | 13 | Mdn $=5.5$ |  |
| Congenital <br> microcephaly | * | + | * | * | * | * | * | * | * | * | * | * | * | * | * | * | * | * | * | * | * | - | * | * | * | * | + | 2/3 | 66.7 |
| ${ }^{\text {Small for }}$ fer | * | + | * | * | * | * | + | + | * | * | * | * | * | * | * | * | * | * | * | * | - | - | * | * | * | * | - | 3/6 | 50 |
| Low weight | + | + | - | * | - | * | + | - | - | * | * | * | * | * | * | * | * | * | * | * | + | * | * | * | * | + | + | 4/10 | 60 |
| Short stature | + | + | - | + | - | * | + | - | - | * | * | * | * | , | * | * | * | - | - | - | - | * | * | * | * | + | + | 6/14 | 42.9 |
| Holoprosencephaly |  |  | * |  | * | * | * | * | * | * | * | * | * | * | * | * | , | + | + | - | * | - | * | * | , | * | - | 2/5 | 40 |
| Microcephaly | + | + | + | + | + | + | + | + | + | + | * | + | + | * | * | * | * | * | + | + | + | + | * | * | * | * | + | 17/17 | 100 |
| Prominent forehead | - | * | * | * | - | + | + | - | * | * | * | - | * | * | * | * | * | * | * | * | * | * | * | * | * | * | + | 3/7 | 42.9 |
| Braquicephaly | + | - | * | * | * | * | - | + | * | * | * | * | * | * | * | * | * | * | * | + | * | * | * | * | * | * | - | 3/6 | 50 |
| Thick eyebrow | + | + | + | + | + | + | + | + | + | + | * | + | * | * | * | * | * | * | + | + | + | + | * | * | * | + | + | 17/17 | 100 |
| Syiophrys | $\pm$ | ${ }_{*}$ | $\stackrel{+}{+}$ | $\stackrel{+}{+}$ | ${ }_{*}^{+}$ | $\stackrel{+}{+}$ | + | + | * | * | * | * | * | * | * | * | * | $\pm$ | * | $\stackrel{+}{+}$ | ${ }_{*}$ | $\pm$ | * | * | * | * | - | 10/13 | 76.9 25 |
| Nistagms | - | * | * | * | * | * | ${ }_{-}^{+}$ | + | * | * | * | * | * | * | * | * | * | * | * | * | * | * | * | * | * | * | - | $1 / 4$ $1 / 4$ $1 / 4$ | 25 25 |
| Long eyelashes | + | + | + | + | + | + | - | + | * | + | * | * | * | * | * | * | * | * | * | * | + | + | * | * | * | + | + | 11/14 | 92.3 |
| Long philtrum | - | + | + | + | - | + | - | + | * | * | * | + | * | * | * | * | * | * | + | + | + | + | * | * | * | * | + | 11/14 | 78.6 |
| Strabismus | * | * | * | * | * | + | + | - | * | * | * | * | * | * | * | * | * | * | * | * | * | * | * | , | * | * | - | 2/4 | 50 |
| ${ }_{\text {Ptosis }}$ | $+$ | * | * | * | + | + | + | - |  | * | * | + | * | * | * | $*$ | * | * | * | * | + | * | * | * | * | * | + | $7 / 8$ $7 / 12$ | 87.5 58.3 |
| Micrognathia Cleft palate | + | - | + | + | + | ${ }^{*}$ | + | - | * | * | * | ${ }_{*}$ | * | * | * | * | * | + | * | + | + | * | * | * | * | + | + | $7 / 12$ $8 / 9$ | 58.3 88.9 |
| Broad uvula | * | * | * | * |  | * | - | + | * | , | * | * | * | * | * | * | * | * | * | * | * | * | * | * | * | * | - | 1/3 | 33.3 |
| Short nose | + | * | * | * | * | - | + | - | * | * | * | + | * | * | * | * | * | * | * | + | + | * | * | * | , | * | + | 6/8 | 75 |
| Nares anteverted | * | * | * | * | * | + | - | + | * | * | * | + | * | * | * | * | * | * | + | * | + | * | * | * | * | + | - | 6/8 | 75 |
| Depressed nasal bridge | + | + | * | * | * | - | + | - | * | * | * | + | * | * | * | * | * | * | * | * | * | * | * | * | * | + | - | 5/8 | ${ }^{62.5}$ |
| High nasal bridge | * | * | * | * | * | + | - | + | * | * | * | - | * | * | * | * | * | * | * | * | * | * | * | * | * | * | + | 3/5 | 60 |
| Increased posterior | + | * | * | * | * | + | + | - | * | * | * | - | * | * | * | * | * | * | * | * | * | * | * | * | * | * | + | 4/6 | 66.7 |
| angulation of ear |  |  | * | * | * | * |  |  |  |  |  |  |  |  |  |  | * |  | + |  |  |  |  |  |  |  |  |  |  |
| Low-set ear | - | * | * | * | * | * | ${ }_{-}^{-}$ | ${ }_{-}^{+}$ | * | * | * | ${ }^{*}$ | * | * | $\stackrel{*}{+}$ | * | * | * | $\stackrel{+}{+}$ | $\stackrel{+}{*}$ | * | * | * | * | * | * | - | $3 / 6$ $2 / 7$ | 50 28.6 |
| Hirsutism | - | - | * | + | * | - | - | + | * | * | * | * | * | * | * | * | * | * | * | * | * | * | * | * | * | * | + | 3/7 | 42.9 |
| Clinodactyly of fitth finger | + | * | * | - | * | + | + | + | * | * | * | * | * | * | * | * | * | * | + | + | + | + | * | * | * | + | - | 9/11 | 81.8 |
| Syndactily of 2-3 | * | * | * | - | * | + | - | + | * | * | * | * | * | * | * | * | * | * | * | * | - | * | * | * | * | * | - | 2/6 | 33.3 |
| Overlapping toes (2-3) | * | * | * | - | * | * | + | - | * | * | * | * | * | * | * | * | * | * | * | * | * | * | * | * | * | * | + | 2/4 | 50 |
| Syndactily of 2-3 toes | * | * | * | - | + | + | + | - | * | * | * | * | * | * | * | * | * | * | * | * | * | * | * | * | * | * | - | 3/6 | 50 |
| Single transverse palmar crease | * | * | * | * | * | * | + | - | * | * | * | * | * | * | * | * | * | * | * | * | * | * | * | * | * | * | - | 1/3 | 33.3 |
| Radio-ulna <br> synostosis, <br> limited elbow <br> range of motion | + | - | * | - | + | * |  |  |  | * | * | * | * | + | + | * | * | * | * | * | - | * | * | * | * | * | + | 5/8 | 62.5 |
| Hemivertebra/butterfly vertebra | + | + | * | * | + | * |  |  |  | * | * | * | * | * | * | * | * | * | - | - | * | * | * | * | * | + | - | 4/10 | 57.1 |
| Pectus excavatum | * | * | * | * | - | * | - | + | * | * | * | * | * | * | * | * | * | * | * | * | * | * | * | * | * | * | - | 1/4 | 25 |
| Pectus crarinatum Congenital heart | * | * | * | * | + | * | - | - | - | * | * | * | * | * | * | * | * | * | * | * | * | * | * | * | * | * | - | 1/5 | 20 |
| Congenita heart disease | * | * | * | * | + | * |  |  |  | * | * | * | * | * | + | * | * | - | * | - | * | * | * | * | * | + | - | 3/6 | 50 |
| Gastroesophageal reflux disease | + | * | * | * | + | * | - | + | * | * | * | * | * | * | * | * | * | * | + | + | + | + | * | * | * | * | - | 7/9 | 77.8 |
| Hypospadias | * | * | * | * | * | * | + | - | n/a | * | * | n/a | n/a | n/a | n/a | * | * | n/a | * | * | * | * | n/a | n/a | * | , | n/a | 1/2 | 50 |
| Cryptorchidism | * | * | * | * | * | * | + | - | n/a | * | * | n/a | n/a | n/a | n/a | * | * | n/a | * | * | + | * | n/a | n/a | * | * | n/a | 2/3 | 66.7 |
| Bilateral inguinal hernia | * | * | * | * | * | * | + | - | n/a | * | * | n/a | n/a | n/a | n/a | * | * | n/a | * | * | * | * | n/a | n/a | * | + | n/a | 2/3 | ${ }_{66.7}$ |
| Congenital |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| diaphragmatic hernia | * | * | * | * | * | * | * | * | n/a | * | * | n/a | n/a | n/a | n/a | * | * | n/a | * | * | + | * | n/a | n/a | * | * | n/a | 1/1 | 100 |
| Bifid scrotum | * | * | * | * | * | * | + | - | n/a | * | * | n/a | n/a | n/a | n/a | * | , | n/a | * | * | * | , | n/a | n/a | * | * | n/a | 1/2 | 50 |

Table 1. Cont.

|  | Deardorff tal. $2012[19](\mathrm{n}=6)$ |  |  |  |  |  | $\begin{aligned} & \text { Minor et al. } \\ & 2014[21] \\ & (n=2) \end{aligned}$ |  |  | $\begin{gathered} \text { Lee etal. } \\ \begin{array}{c} 101412] \\ (\mathrm{n}=1) \end{array} \end{gathered}$ | $\left.\begin{array}{c} \text { Martinez } \\ \text { ata } \\ \text { chat } 2017 \\ \mathrm{n}=17 \end{array}\right)$ | Boyle etal. $2017[24](\mathrm{n}=4)$ |  |  |  | $\begin{gathered} \text { Yuan et al. } \\ 2019[25] \\ (n=2) \end{gathered}$ |  | Kruske etal. 2019 |  |  | $\begin{gathered} \text { Gudmunon } \\ \text { etal. } 2 \text { ong } \\ {[6](\mathrm{n}=1)} \end{gathered}$ | Dorval et al. ( $\mathrm{n}=1$ ) | Latorre-Pelliceret al. 2020 [28] |  |  |  |  | Total ( $\mathrm{N}=26)$ | (\%) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 1 | 2 | 3 | 4 | 5 | 6 |  |  |  |  |  | 1 | 2 | 3 | 4 |  |  | 1 |  | 3 |  |  | 1 |  | 3 |  |  |  |  |
| $\underbrace{}_{\substack{\text { Penoscrotal } \\ \text { transposition }}}$ | * | + | * | * | * | * | + | - | n/a | * | * | n/a | n/a | n/a | n/a | * | * | n/a | * | * | * | * | n/a | n/a | * | * | n/a | 2/3 | ${ }_{66} 6$ |
| (tancosition | - | * | + | * | + | * | + | + | . | * | * | . | . | * | . | . | * | + | + | + | + | - | * | * | . | * | - | 8/11 | 72.7 |
| ${ }_{\text {deay }}$ Language delay | - | + | + | * | + | . | + | - | , | + | * | * | * | . | * | , | * | * | * | * | * | + | * | * | * | * | - | 6/9 | ${ }_{66} 7$ |
| Motor delay |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | * | - | * |  | * | * | - | 3/7 |  |
|  | - | * | * | * | + | * | + |  | * | * | * | * | * | * | * | * | * | * | . | * | * | * | * | * | * | * | - | 2/4 | 50 |
| Steremicicerning | - | * | * | * | * | . | - | + | * | * | * | + | + | + | + | * | * | * | * | * | * | * | * | . | * | * | - | 5/8 | ${ }_{62} 5$ |
| dita | - | * | + | + | * | * |  |  |  | * | * | * | * | . | * | . | * | * | * | * | - | - | * | * | . | + | - | 3/7 | 429 |
| disab | - | * | * | . |  | * | + | + | * | * | * | * | * | * | * | * | * | * | * | * | * | * | * | * | * | * | - | 2/4 | 50 |
| Cutis marmorata | + | + | * | - |  | - | * | * | * | * | * | * | * | * | * | * | * | * | * | * | * | * | * | . | * | * | + | 3/5 | 60 |
| $\underbrace{\text { a }}_{\substack{\text { Preaxial } \\ \text { polydactyly }}}$ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | + | 1/1 | 100 |
| Cill | * | * | * | * | * | * | * | * | * | * | * | * | * | * | * | * | * | * | * | * | * | * | * | - | 10 | * | $\pm$ | 1/1 | 100 |
|  | 8.11 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 8:116844545_116859996 ${ }^{\text {F }}$ |  |  |
| VariantExon | ${ }_{8,71}^{7,70}$ | ${ }_{\substack{\text { \%,96 } \\ 0,90}}$ | ${ }_{789}^{723}$ | ${ }_{\text {c, }}^{\substack{\text { a, } \\ 0}}$ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | ${ }_{653}^{177}$ | ${ }_{653}^{177}$ |  |  |  |  |  |  |
|  |  |  | O-1 226 |  | $\substack{\text { c.11 } \\ 27 C}_{\text {cher }}$ | $\mathrm{c}_{53}^{\mathrm{c}, 17}$ | (iole | ${ }_{2.5}^{\text {c.59 }}$ | * |  | c.866>A | ${ }_{\substack{\text { c.70 } \\ 4 \text { de }}}$ | $\substack{\text { c.70 } \\ \text { de }}_{\text {de }}$ |  | ${ }_{4}^{c}$ | $\substack{c \\ \text { cidu } \\ \text { sou }}^{\text {d }}$ | ${ }_{\text {c.11 }}^{61+}$ | $\substack { \text { c.15 } \\ \begin{subarray}{c}{\text { cid } \\ \text { lin }{ \text { c.15 } \\ \begin{subarray} { c } { \text { cid } \\ \text { lin } } } \end{subarray}_{\text {dr }}$ | ${ }_{\substack{\text { c.58 } \\ 905}}$ | ${ }_{\substack{\text { c. } \\ 172 \\ 1724 \\ 224}}$ | ${ }_{7}^{7}$ |  | c.13 | ${ }_{224}^{261}$ | che <br> 118 <br> 118 | $\underset{\substack{\text { cincon } \\ \text { 2374 }}}{\text { and }}$ |  |  |  |  |  |
|  | ${ }_{24,1}^{21,0}$ | 19,3 <br> 30,0 | ${ }_{316}^{226}$ | 18,9 <br> 48,4 <br> 8 |  |  |  |  |  | ${ }_{\text {ost>C }}$ |  |  |  |  |  |  |  |  |  |  |  |  |  | ${ }_{945}^{224}$ | ${ }_{270}^{118}$ | ${ }_{000}{ }^{2394}$ |  |  |  |  |  |
|  | $\stackrel{93}{8}$ | $\stackrel{85}{8}$ | ¢ | 86 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | ${ }_{5}^{96}$ | ${ }^{323}$ |  |  |  |  |  |  |
|  | ${ }_{14}^{1-}$ | ${ }_{14}^{1-}$ | ${ }_{14}^{1-}$ | ${ }_{14}^{1-}$ | 9 | 14 | 13 | 3 |  | 14 | 2 | 7 | 7 | 7 | 7 | 12 | Intro | 12 | 6 | 10 | 14 | 9 | 11 | ${ }_{1-}$ | ${ }_{1-}$ | 1-14 | 9-14 |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Type of variant | cnv | cnv | cnv | cnv | ${ }^{\text {Miss }}$ | ${ }^{\text {Miss }}$ | ${ }_{\text {Prame }}^{\text {pb }}$ | Frame | Splicing s site | Misense | Codors stop | ${ }_{\text {codon }}$ | ${ }_{\text {colon }}$ | ${ }_{\text {codon }}$ | ${ }_{\text {caton }}$ | Frame | Splicing |  |  | ${ }_{\text {Frame }}$ | ${ }_{\text {Frame }}$ | Codon stop | Miss | cNV | cnv | cnv | Frameshift |  |  |
| Classification |  |  |  |  |  |  |  |  |  | ${ }_{\text {LP }}$ | LP | P | P | P | P |  |  | p | P | P | LP | p | vus | p | P | p |  |  |  |

$\mathrm{n} / \mathrm{a}=$ not applicable; VUS-LB = variant of uncertain significance or likely benign; * non-descript. $\mathrm{F}=$ female; $\mathrm{M}=$ male; Mdn = median; $\mathrm{P}=$ pathogenic; $\mathrm{LP}=$ likely-pathogenic; ADHD $=$ attention deficit and hyperactivity disorder; $s=\mathrm{hg} 18 ; \mathrm{F}=\mathrm{hg} 19$.

This study is the first to show a de novo intragenic deletion in RAD21, detected via high-resolution CMA, that is associated with CdLS type 4. In addition, the patient described in this study showed clinical manifestations previously unreported for CdLS type 4 patients, such as uterus malformations and preaxial polydactylies [6,8,20-29]. These characteristics could be unusual signs of CdLS or could be the result of other variants, such as SNVs, that cannot be detected via the techniques used in this study. To test this hypothesis, an NGS analysis is suggested. However, considering the clinical manifestations, the high-resolution CMA results obtained for the proband and her parents, and the literature reviewed, we believe that the CNV found in the present study is likely pathogenic and could cause the patient's phenotype.

Author Contributions: Conceptualization, H.H.A.-B.; Methodology, H.H.A.-B., F.V.S., and R.P.L.; Formal Analysis, F.V.S. and R.P.L. Genomic Data Curation, R.P.L.; Writing-Original Draft Preparation, H.H.A.-B., F.V.S., and R.P.L.; Writing-Review and Editing, H.H.A.-B., F.V.S., and R.P.L.; Visualization, H.H.A.-B.; Supervision, H.H.A.-B. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.
Institutional Review Board Statement: Not applicable.
Informed Consent Statement: Written informed consent has been obtained from the child's parents to publish this paper.

Data Availability Statement: All data underlying the results are available as part of the article and no additional source data are required.

Acknowledgments: We acknowledge Johnny De la Cruz for administrative support toward publication.
Conflicts of Interest: The authors declare no conflict of interest.

## References

1. OMIM-Online Mendelian Inheritance in Man. Available online: http:/ / www.omim.org / (accessed on 15 May 2016).
2. Kline, A.D.; Moss, J.F.; Selicorni, A.; Bisgaard, A.-M.; Deardorff, M.A.; Gillett, P.M.; Ishman, S.L.; Kerr, L.M.; Levin, A.V.; Mulder, P.A.; et al. Diagnosis and management of Cornelia de Lange syndrome: First international consensus statement. Nat. Rev. Genet. 2018, 19, 649-666. [CrossRef] [PubMed]
3. Parenti, I.; Kaiser, F.J. Cornelia de Lange Syndrome as Paradigm of Chromatinopathies. Front. Neurosci. 2021, 15, 774950. [CrossRef] [PubMed]
4. Kline, A.D.; Krantz, I.D.; Sommer, A.; Kliewer, M.; Jackson, L.G.; FitzPatrick, D.R.; Levin, A.V.; Selicorni, A. Cornelia de Lange syndrome: Clinical review, diagnostic and scoring systems, and anticipatory guidance. Am. J. Med. Genet. A 2007, 143A, 1287-1296. [CrossRef] [PubMed]
5. Deschamps, G.N. Cornelia de Lange Syndrome. Neonatal. Netw. 2022, 41, 145-149. [CrossRef] [PubMed]
6. Gudmundsson, S.; Annerén, G.; Marcos-Alcalde, Í.; Wilbe, M.; Melin, M.; Gómez-Puertas, P.; Bondeson, M.-L. A novel RAD21 p.(Gln592del) variant expands the clinical description of Cornelia de Lange syndrome type 4-Review of the literature. Eur. J. Med. Genet. 2019, 62, 103526. [CrossRef] [PubMed]
7. Bonora, E.; Bianco, F.; Cordeddu, L.; Bamshad, M.; Francescatto, L.; Dowless, D.; Stanghellini, V.; Cogliandro, R.F.; Lindberg, G.; Mungan, Z.; et al. Mutations in RAD21 disrupt regulation of APOB in patients with chronic intestinal pseudo-obstruction. Gastroenterology 2015, 148, 771-782.e11. [CrossRef] [PubMed]
8. Krab, L.C.; Marcos-Alcalde, I.; Assaf, M.; Balasubramanian, M.; Andersen, J.B.; Bisgaard, A.-M.; Fitzpatrick, D.R.; Gudmundsson, S.; Huisman, S.A.; Kalayci, T.; et al. Delineation of phenotypes and genotypes related to cohesin structural protein RAD21. Hum. Genet. 2020, 139, 575-592. [CrossRef]
9. McKay, M.J.; Troelstra, C.; Kanaar, R.; Smit, B.; Hagemeijer, A.; Bootsma, D.; Hoeijmakers, J.H. Sequence conservation of the rad21 Schizosaccharomyces pombe DNA double-strand break repair gene in human and mouse. Genomics 1996, 36, 305-315. [CrossRef]
10. Sumara, I.; Vorlaufer, E.; Gieffers, C.; Peters, B.H.; Peters, J.-M. Characterization of Vertebrate Cohesin Complexes and Their Regulation in Prophase. J. Cell Biol. 2000, 151, 749-762. [CrossRef]
11. Cheng, H.; Zhang, N.; Pati, D. Cohesin subunit RAD21: From biology to disease. Gene 2020, 758, 144966. [CrossRef]
12. Xu, H.; Balakrishnan, K.; Malaterre, J.; Beasley, M.; Yan, Y.; Essers, J.; Appeldoorn, E.; Thomaszewski, J.M.; Vazquez, M.; McKay, M.J.; et al. Rad21-cohesin haploinsufficiency impedes DNA repair and enhances gastrointestinal radiosensitivity in mice. PLoS ONE 2010, 5, e12112. [CrossRef]
13. Chen, F.; Kamradt, M.; Mulcahy, M.; Byun, Y.; Xu, H.; McKay, M.J.; Cryns, V.L. Caspase proteolysis of the cohesin component RAD21 promotes apoptosis. J. Biol. Chem. 2002, 277, 16775-16781. [CrossRef] [PubMed]
14. Pati, D.; Zhang, N.; Plon, S.E. Linking sister chromatid cohesion and apoptosis: Role of Rad21. Mol. Cell. Biol. 2002, 22, 8267-8277. [CrossRef] [PubMed]
15. Beauchene, N.A.; Díaz-Martínez, L.A.; Furniss, K.; Hsu, W.-S.; Tsai, H.-J.; Chamberlain, C.; Esponda, P.; Giménez-Abián, J.F.; Clarke, D.J. Rad21 is required for centrosome integrity in human cells independently of its role in chromosome cohesion. Cell Cycle 2010, 9, 1774-1780. [CrossRef]
16. Seitan, V.C.; Hao, B.; Tachibana-Konwalski, K.; Lavagnolli, T.; Mira-Bontenbal, H.; Brown, K.E.; Teng, G.; Carroll, T.; Terry, A.; Horan, K.; et al. A role for cohesin in T-cell-receptor rearrangement and thymocyte differentiation. Nature 2011, 476, 467-471. [CrossRef]
17. Fisher, J.B.; Peterson, J.; Reimer, M.; Stelloh, C.; Pulakanti, K.; Gerbec, Z.J.; Abel, A.M.; Strouse, J.M.; Strouse, C.; McNulty, M.; et al. The cohesin subunit Rad21 is a negative regulator of hematopoietic self-renewal through epigenetic repression of Hoxa7 and Hoxa9. Leukemia 2017, 31, 712-719. [CrossRef]
18. Zhang, Y.; da Fang, Y. Progresses on the structure and function of cohesin. Hereditas 2020, 42, 57-72.
19. Deardorff, M.A.; Wilde, J.J.; Albrecht, M.; Dickinson, E.; Tennstedt, S.; Braunholz, D.; Mönnich, M.; Yan, Y.; Xu, W.; Gil-Rodríguez, M.C.; et al. RAD21 Mutations Cause a Human Cohesinopathy. Am. J. Hum. Genet. 2012, 90, 1014. [CrossRef]
20. Ansari, M.; Poke, G.; Ferry, Q.; Williamson, K.; Aldridge, R.; Meynert, A.M.; Bengani, H.; Chan, C.Y.; Kayserili, H.; Avci, Ş.; et al. Genetic heterogeneity in Cornelia de Lange syndrome (CdLS) and CdLS-like phenotypes with observed and predicted levels of mosaicism. J. Med. Genet. 2014, 51, 659-668. [CrossRef]
21. Minor, A.; Shinawi, M.; Hogue, J.S.; Vineyard, M.; Hamlin, D.R.; Tan, C.; Donato, K.; Wysinger, L.; Botes, S.; Das, S.; et al. Two novel RAD21 mutations in patients with mild Cornelia de Lange syndrome-like presentation and report of the first familial case. Gene 2014, 537, 279-284. [CrossRef]
22. Lee, H.; Deignan, J.L.; Dorrani, N.; Strom, S.P.; Kantarci, S.; Quintero-Rivera, F.; Das, K.; Toy, T.; Harry, B.; Yourshaw, M.; et al. Clinical exome sequencing for genetic identification of rare Mendelian disorders. JAMA 2014, 312, 1880-1887. [CrossRef] [PubMed]
23. Martínez, F.; Caro-Llopis, A.; Roselló, M.; Oltra, S.; Mayo, S.; Monfort, S.; Orellana, C. High diagnostic yield of syndromic intellectual disability by targeted next-generation sequencing. J. Med. Genet. 2017, 54, 87-92. [CrossRef] [PubMed]
24. Boyle, M.I.; Jespersgaard, C.; Nazaryan, L.; Ravn, K.; Brøndum-Nielsen, K.; Bisgaard, A.-M.; Tümer, Z. Deletion of 11q12.3-11q13.1 in a patient with intellectual disability and childhood facial features resembling Cornelia de Lange syndrome. Gene 2015, 572, 130-134. [CrossRef] [PubMed]
25. Yuan, B.; Neira, J.; Pehlivan, D.; Santiago-Sim, T.; Song, X.; Rosenfeld, J.; Posey, J.E.; Patel, V.; Jin, W.; Adam, M.P. Clinical exome sequencing reveals locus heterogeneity and phenotypic variability of cohesinopathies. Genet. Med. Off. J. Am. Coll. Med. Genet. 2019, 21, 663-675. [CrossRef]
26. Kruszka, P.; Berger, S.I.; Casa, V.; Dekker, M.R.; Gaesser, J.; Weiss, K.; Martinez, A.F.; Murdock, D.R.; Louie, R.J.; Prijoles, E.J.; et al. Cohesin complex-associated holoprosencephaly. Brain 2019, 142, 2631-2643. [CrossRef]
27. Dorval, S.; Masciadri, M.; Mathot, M.; Russo, S.; Revencu, N.; Larizza, L. A novel RAD21 mutation in a boy with mild Cornelia de Lange presentation: Further delineation of the phenotype. Eur. J. Med. Genet. 2020, 63, 103620. [CrossRef]
28. Latorre-Pellicer, A.; Ascaso, Á.; Trujillano, L.; Gil-Salvador, M.; Arnedo, M.; Lucia-Campos, C.; Antoñanzas-Pérez, R.; MarcosAlcalde, I.; Parenti, I.; Bueno-Lozano, G.; et al. Evaluating Face2Gene as a Tool to Identify Cornelia de Lange Syndrome by Facial Phenotypes. Int. J. Mol. Sci. 2020, 21, 1042. [CrossRef]
29. Lei, M.; Liang, D.; Yang, Y.; Mitsuhashi, S.; Katoh, K.; Miyake, N.; Frith, M.C.; Wu, L.; Matsumoto, N. Long-read DNA sequencing fully characterized chromothripsis in a patient with Langer-Giedion syndrome and Cornelia de Lange syndrome-4. J. Hum. Genet. 2020, 65, 667-674. [CrossRef]
30. Abarca-Barriga, H.H.; Vásquez-Sotomayor, F. Utilidad diagnóstica de la secuenciación de segunda y tercera generación en pacientes con discapacidad intelectual: Revisión rápida. Psiquiatr. Biológica 2023, 30, 100392. [CrossRef]
31. Kopanos, C.; Tsiolkas, V.; Kouris, A.; Chapple, C.E.; Aguilera, M.A.; Meyer, R.; Massouras, A. VarSome: The human genomic variant search engine. Bioinformatics 2019, 35, 1978-1980. [CrossRef]
32. Rodrigues, E.d.S.; Griffith, S.; Martin, R.; Antonescu, C.; Posey, J.E.; Coban-Akdemir, Z.; Jhangiani, S.N.; Doheny, K.F.; Lupski, J.R.; Valle, D.; et al. Variant-level matching for diagnosis and discovery: Challenges and opportunities. Hum. Mutat. 2022, 43, 782-790. [CrossRef] [PubMed]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

